150 related articles for article (PubMed ID: 29805754)
1. Levels of miR-126 and miR-218 are elevated in ductal carcinoma
Volinia S; Bertagnolo V; Grassilli S; Brugnoli F; Manfrini M; Galasso M; Scatena C; Mazzanti CM; Lessi F; Naccarato G; Caligo A; Bianchini E; Piubello Q; Orvieto E; Rugge M; Natali C; Reale D; Vecchione A; Warner S; Croce CM; Capitani S
Oncotarget; 2018 May; 9(34):23543-23553. PubMed ID: 29805754
[TBL] [Abstract][Full Text] [Related]
2. miR-106b-5p and miR-17-5p could predict recurrence and progression in breast ductal carcinoma in situ based on the transforming growth factor-beta pathway.
Lee J; Kim HE; Song YS; Cho EY; Lee A
Breast Cancer Res Treat; 2019 Jul; 176(1):119-130. PubMed ID: 30989460
[TBL] [Abstract][Full Text] [Related]
3. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
[TBL] [Abstract][Full Text] [Related]
4. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
5. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
[TBL] [Abstract][Full Text] [Related]
6. Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer.
Kim SY; Jung SH; Kim MS; Baek IP; Lee SH; Kim TM; Chung YJ; Lee SH
Oncotarget; 2015 Apr; 6(10):7597-607. PubMed ID: 25831047
[TBL] [Abstract][Full Text] [Related]
7. Exosome-encapsulated microRNA-223-3p as a minimally invasive biomarker for the early detection of invasive breast cancer.
Yoshikawa M; Iinuma H; Umemoto Y; Yanagisawa T; Matsumoto A; Jinno H
Oncol Lett; 2018 Jun; 15(6):9584-9592. PubMed ID: 29805680
[TBL] [Abstract][Full Text] [Related]
8. Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival.
Dieterich M; Hartwig F; Stubert J; Klöcking S; Kundt G; Stengel B; Reimer T; Gerber B
Breast; 2014 Aug; 23(4):346-51. PubMed ID: 24559611
[TBL] [Abstract][Full Text] [Related]
9. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
von Minckwitz G; Darb-Esfahani S; Loibl S; Huober J; Tesch H; Solbach C; Holms F; Eidtmann H; Dietrich K; Just M; Clemens MR; Hanusch C; Schrader I; Henschen S; Hoffmann G; Tiemann K; Diebold K; Untch M; Denkert C
Breast Cancer Res Treat; 2012 Apr; 132(3):863-70. PubMed ID: 21667238
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-132 is frequently down-regulated in ductal carcinoma in situ (DCIS) of breast and acts as a tumor suppressor by inhibiting cell proliferation.
Li S; Meng H; Zhou F; Zhai L; Zhang L; Gu F; Fan Y; Lang R; Fu L; Gu L; Qi L
Pathol Res Pract; 2013 Mar; 209(3):179-83. PubMed ID: 23399321
[TBL] [Abstract][Full Text] [Related]
11. Genomic differences between pure ductal carcinoma in situ of the breast and that associated with invasive disease: a calibrated aCGH study.
Iakovlev VV; Arneson NC; Wong V; Wang C; Leung S; Iakovleva G; Warren K; Pintilie M; Done SJ
Clin Cancer Res; 2008 Jul; 14(14):4446-54. PubMed ID: 18628458
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the association of mammographic density and clinical factors with ductal carcinoma in situ versus invasive ductal breast cancer in Korean women.
Ko H; Shin J; Lee JE; Nam SJ; Nguyen TL; Hopper JL; Song YM
BMC Cancer; 2017 Dec; 17(1):821. PubMed ID: 29207971
[TBL] [Abstract][Full Text] [Related]
13. Grade of ductal carcinoma in situ accompanying infiltrating ductal carcinoma as an independent prognostic factor.
Kim JY; Han W; Moon HG; Park IA; Ahn SK; Kim J; Lee JW; Kim T; Kim MK; Noh DY
Clin Breast Cancer; 2013 Oct; 13(5):385-91. PubMed ID: 23870857
[TBL] [Abstract][Full Text] [Related]
14. Pure ductal carcinoma in situ and in situ component of ductal invasive carcinoma of the breast. A preliminary morphometric study.
Giardina C; Serio G; Lepore G; Lettini T; Dalena AM; Pennella A; D'Eredità G; Valente T; Ricco R
J Exp Clin Cancer Res; 2003 Jun; 22(2):279-88. PubMed ID: 12866579
[TBL] [Abstract][Full Text] [Related]
15. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression.
Subramaniam MM; Chan JY; Soong R; Ito K; Ito Y; Yeoh KG; Salto-Tellez M; Putti TC
Breast Cancer Res Treat; 2009 Jan; 113(1):113-21. PubMed ID: 18256927
[TBL] [Abstract][Full Text] [Related]
16. Genetic pathways in the evolution of breast ductal carcinoma in situ.
Farabegoli F; Champeme MH; Bieche I; Santini D; Ceccarelli C; Derenzini M; Lidereau R
J Pathol; 2002 Mar; 196(3):280-6. PubMed ID: 11857490
[TBL] [Abstract][Full Text] [Related]
17. Transcriptome analysis reveals differences in cell cycle, growth and migration related genes that distinguish fibroblasts derived from pre-invasive and invasive breast cancer.
Fang WB; Medrano M; Cote P; Portsche M; Rao V; Hong Y; Behbod F; Knapp JR; Bloomer C; Noel-Macdonnell J; Cheng N
Front Oncol; 2023; 13():1130911. PubMed ID: 37091166
[TBL] [Abstract][Full Text] [Related]
18. Selection and evolution in the genomic landscape of copy number alterations in ductal carcinoma in situ (DCIS) and its progression to invasive carcinoma of ductal/no special type: a meta-analysis.
Rane SU; Mirza H; Grigoriadis A; Pinder SE
Breast Cancer Res Treat; 2015 Aug; 153(1):101-21. PubMed ID: 26255059
[TBL] [Abstract][Full Text] [Related]
19. Positive enhancement integral values in dynamic contrast enhanced magnetic resonance imaging of breast carcinoma: ductal carcinoma in situ vs. invasive ductal carcinoma.
Nadrljanski M; Maksimović R; Plešinac-Karapandžić V; Nikitović M; Marković-Vasiljković B; Milošević Z
Eur J Radiol; 2014 Aug; 83(8):1363-7. PubMed ID: 24894697
[TBL] [Abstract][Full Text] [Related]
20. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
